Table 1 Clinical and pathological characteristics
Characteristics | N | % |
|---|---|---|
Gender | ||
 Male | 191 | 69.2 |
 Female | 85 | 30.8 |
Age | ||
 < 65 | 167 | 60.5 |
 ≥ 65 | 109 | 39.5 |
Smoker | ||
 No | 88 | 31.9 |
 Yes | 188 | 68.1 |
Histology | ||
 Adenocarcinoma | 140 | 50.7 |
 Squamous cell carcinoma | 136 | 49.3 |
Distant metastasis | ||
 No | 180 | 65.2 |
 Yes | 96 | 34.8 |
EGFR mutation | ||
 No | 96 | 59.6 |
 Yes | 65 | 40.4 |
PD-L1expression | ||
 < 50% | 86 | 66.2 |
 ≥ 50% | 44 | 33.8 |
Treatment line | ||
 Immunotherapy group | ||
  First line | 102 | 66.7 |
  Second line and beyond | 51 | 33.3 |
 Chemotherapy group | ||
  First line | 96 | 78.0 |
  Second line and beyond | 27 | 22.0 |
Treatment model | ||
 Immunotherapy group | ||
  ICIs alone | 22 | 14.4 |
  Chemotherapy combined with ICIs | 125 | 81.7 |
  Anti-angiogenesis drugs combined with ICIs | 6 | 3.9 |
 Chemotherapy group | ||
  Chemotherapy alone | 115 | 93.5 |
  Chemotherapy combined with Anti-angiogenesis drugs | 8 | 6.5 |